ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
2
3
4
5
6
COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide
Tuesday, July 06, 2021
7
All
8
Phase 1
9
Phase 1/2
10
Phase 2
11
Phase 2/3
12
Phase 3
13
Phase 4
14
Summary Information on Vaccine Products in Clinical Development
15
16
17
18
1. - Number of vaccines in clinical development
105
19
20
2. - Number of vaccines in pre-clinical development
184
Vaccines in clinical development
105
21
22
Vaccines in pre-clinical development
184
23
24
25
3. - Candidates in clinical phase
26
27
FilterAll
Select phase of development (default is all)
28
29
Platform
Candidate vaccines (no. and %)
30
PSProtein subunit3432%
31
VVnrViral Vector (non-replicating)1514%
32
DNADNA1010%
33
IVInactivated Virus1615%
34
RNARNA1817%
35
VVrViral Vector (replicating)22%
36
VLPVirus Like Particle55%
37
VVr + APCVVr + Antigen Presenting Cell22%
38
LAVLive Attenuated Virus22%
39
VVnr + APCVVnr + Antigen Presenting Cell11%
40
105
41
42
43
44
4. - Number of doses, schedule and route of administration of candidates in clinical phase
45
46
Number of doses & schedule
Candidate vaccines (no. and %)
47
1 dose1514%1 dose15
48
Day 0152 doses68
49
2 doses6865%3 doses1
50
Day 0 + 146
other not specified
21
51
Day 0 + 2126
52
Day 0 + 2836Day 015
53
3 doses11%
Day 0 + 14
6
54
Day 0 + 28 + 561
Day 0 + 21
26
55
TBD / No Data (ND)
2120%
Day 0 + 28
36
56
105
Day 0 + 28 + 56
1
57
Route of administration
other not specified
21
58
Oral33%
59
Injectable8985%
60
SCSub cutaneous55%
61
IDIntra dermal44%
62
IMIntra muscular8076%
63
INIntra nasal77%
64
TBD / No Data (ND)
1312%
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100